Caladrius Biosciences (NASDAQ:CLBS) has been assigned a $7.00 price objective by research analysts at HC Wainwright in a report released on Friday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 70.32% from the stock’s current price.
Separately, Zacks Investment Research raised Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $4.25 price objective for the company in a research note on Tuesday, September 26th.
Shares of Caladrius Biosciences (CLBS) traded up $0.05 during trading on Friday, reaching $4.11. The company had a trading volume of 16,194 shares, compared to its average volume of 53,630. Caladrius Biosciences has a 52 week low of $2.63 and a 52 week high of $7.79. The company has a market capitalization of $38.46, a price-to-earnings ratio of 1.95 and a beta of 1.59.
A hedge fund recently raised its stake in Caladrius Biosciences stock. Vanguard Group Inc. increased its holdings in shares of Caladrius Biosciences Inc (NASDAQ:CLBS) by 2.8% in the second quarter, according to its most recent filing with the SEC. The fund owned 155,380 shares of the biotechnology company’s stock after acquiring an additional 4,163 shares during the period. Vanguard Group Inc.’s holdings in Caladrius Biosciences were worth $723,000 at the end of the most recent quarter. Institutional investors and hedge funds own 6.41% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/20/caladrius-biosciences-clbs-pt-set-at-7-00-by-hc-wainwright.html.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.